{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:34:46Z","timestamp":1784669686579,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Project of Beijing Youan Hospital, CCMU","award":["2019 (BJYAYY-GG2019-05)"],"award-info":[{"award-number":["2019 (BJYAYY-GG2019-05)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with primary biliary cholangitis (PBC) often have comorbid dyslipidemia, and determining the degree of hepatic steatosis can help predict the risk of cardiovascular events in PBC patients. The aim of our study was to analyze the characteristics of lipid distribution and the degree of hepatic steatosis in PBC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analyzed 479 cases of PBC, chronic hepatitis B (CHB), chronic hepatitis C (CHC), non-alcoholic fatty liver disease (NAFLD), and healthy subjects (Normal) diagnosed by liver biopsy or definitive clinical diagnosis. Controlled attenuation parameter (CAP) values were applied to assess the degree of steatosis of the liver, and lipid levels were also compared in the five cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found that among the five groups of subjects, the PBC group had the lowest CAP values (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), and the high-density lipoprotein cholesterol (HDL-C) level in the PBC group was higher than normal, CHC and CHB group (<jats:italic>P<\/jats:italic>\u2009=\u20090.004,<jats:italic>P<\/jats:italic>\u2009=\u20090.033,<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, respectively).In the multivariate linear analysis, only BMI (\u03b2\u2009=\u20091.280,<jats:italic>P<\/jats:italic>\u2009=\u20090.028), ALP (\u03b2\u2009=\u2009\u2212\u20090.064,<jats:italic>P<\/jats:italic>\u2009=\u20090.012), TBA (\u03b2\u2009=\u2009\u2212\u20090.126,<jats:italic>P<\/jats:italic>\u2009=\u20090.020), TG (\u03b2\u2009=\u200912.520,<jats:italic>P<\/jats:italic>\u2009=\u20090.000), HDL-C (\u03b2\u2009=\u2009\u2212\u200911.338,<jats:italic>P<\/jats:italic>\u2009=\u20090.001) and LDL-C (\u03b2\u2009=\u20097.012,<jats:italic>P<\/jats:italic>\u2009=\u20090.002) were independent predictors of CAP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among PBC, CHB, CHC, NAFLD and healthy subjects, PBC had the lowest degree of hepatic steatosis and higher HDL-C levels, all of which were found to be protective factors against atherosclerosis and cardiovascular risk and would provide a valuable reference for the risk of developing cardiovascular events in PBC patients.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12876-021-01974-4","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T08:03:54Z","timestamp":1634889834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The liver steatosis severity and lipid characteristics in primary biliary cholangitis"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tieying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fankun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"67","key":"1974_CR1","first-page":"145","volume":"2017","author":"European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;2017(67):145\u201372.","journal-title":"J Hepatol"},{"key":"1974_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/gut.51.2.265","volume":"51","author":"M Longo","year":"2002","unstructured":"Longo M, Crosignani A, Battezzati PM, Giussani CS, Invernizzi P, Zuin M, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut. 2002;51:265\u20139.","journal-title":"Gut"},{"key":"1974_CR3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00508-012-0162-9","volume":"124","author":"T Alempijevic","year":"2012","unstructured":"Alempijevic T, Sokic-Milutinovic A, Pavlovic Markovic A, Jesic-Vukicevic R, Milicic B, Macut D, et al. Assessment of metabolic syndrome in patients with primary biliary cirrhosis. Wien Klin Wochenschr. 2012;124:251\u20135.","journal-title":"Wien Klin Wochenschr"},{"key":"1974_CR4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","volume":"26","author":"MV Machado","year":"2011","unstructured":"Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis c infected patients. J Gastroenterol Hepatol. 2011;26:1361\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1974_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589\u2013600.","journal-title":"J Hepatol"},{"key":"1974_CR6","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.jhep.2014.01.017","volume":"60","author":"A Berzigotti","year":"2014","unstructured":"Berzigotti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis. J Hepatol. 2014;60:910\u20132.","journal-title":"J Hepatol"},{"key":"1974_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"key":"1974_CR8","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/jgh.12134","volume":"28","author":"M Kumar","year":"2013","unstructured":"Kumar M, Rastogi A, Singh T, Behari C, Gupta E, Garg H, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance? J Gastroenterol Hepatol. 2013;28:1194\u2013201.","journal-title":"J Gastroenterol Hepatol"},{"key":"1974_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","volume":"5","author":"SK Sarin","year":"2020","unstructured":"Sarin SK, Kumar M, Eslam M, George J, Mahtab MA, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: A Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5:167\u2013228.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1974_CR10","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jfma.2017.08.010","volume":"116","author":"YH Yen","year":"2017","unstructured":"Yen YH, Chen JF, Wu CK, Lin MT, Chang KC, Tseng PL, et al. The correlation of controlled attenuation parameter results with ultrasound-identified steatosis in real-world clinical practice. J Formos Med Assoc. 2017;116:852\u201361.","journal-title":"J Formos Med Assoc"},{"key":"1974_CR11","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/hepr.12094","volume":"43","author":"K Masaki","year":"2013","unstructured":"Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res. 2013;43:1182\u20139.","journal-title":"Hepatol Res"},{"key":"1974_CR12","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"1974_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/hep.31060","volume":"71","author":"MG Ghany","year":"2020","unstructured":"Ghany MG, Morgan TR, AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis c virus infection. Hepatology. 2020;71:686\u2013721.","journal-title":"Hepatology"},{"key":"1974_CR14","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1478-3231.2012.02781.x","volume":"32","author":"RP Myers","year":"2012","unstructured":"Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32:902\u201310.","journal-title":"Liver Int"},{"key":"1974_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de L\u00e9dinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66:1022\u201330.","journal-title":"J Hepatol"},{"key":"1974_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrendo.2016.210","volume":"13","author":"PM Hunter","year":"2017","unstructured":"Hunter PM, Hegele RA. Fouctional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13:278\u201388.","journal-title":"Nat Rev Endocrinol"},{"key":"1974_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0032-1306423","volume":"32","author":"H Chatrath","year":"2012","unstructured":"Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32:22\u20139.","journal-title":"Semin Liver Dis"},{"key":"1974_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2010.05.037","volume":"54","author":"P Simonen","year":"2011","unstructured":"Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54:153\u20139.","journal-title":"J Hepatol"},{"key":"1974_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1365-2893.2005.00655.x","volume":"13","author":"D Siagris","year":"2006","unstructured":"Siagris D, Christofidou M, Theocharis GJ, Pagoni N, Papadimitriou C, Lekkou A, et al. Serum lipid pattern in chronic hepatitis C: histological and virological corrrelations. J Viral Hepat. 2006;13:56\u201361.","journal-title":"J Viral Hepat"},{"key":"1974_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jhep.2011.09.013","volume":"56","author":"VW Wong","year":"2012","unstructured":"Wong VW, Wong GL, Chu WC, Chim AM, Ong A, Yeung DK, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533\u201340.","journal-title":"J Hepatol"},{"key":"1974_CR21","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/BF01536666","volume":"33","author":"G Baldo-Enzi","year":"1988","unstructured":"Baldo-Enzi G, Baiocchi MR, Grotto M, Floreani AR, Zagolin M, Chiaramonte M, et al. Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects. Dig Dis Sci. 1988;33:1201\u20137.","journal-title":"Dig Dis Sci"},{"key":"1974_CR22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/0016-5085(85)90642-0","volume":"89","author":"CE Jahn","year":"1985","unstructured":"Jahn CE, Schaefer EJ, Taam LA, Hoofnagle JH, Lindgren FT, Albers JJ, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. 1985;89:1266\u201378.","journal-title":"Gastroenterology"},{"key":"1974_CR23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","volume":"13","author":"MS Siddiqui","year":"2015","unstructured":"Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13:1000-1008.e3.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1974_CR24","doi-asserted-by":"publisher","first-page":"11691","DOI":"10.1038\/s41598-018-29639-5","volume":"8","author":"R Fadaei","year":"2018","unstructured":"Fadaei R, Poustchi H, Meshkani R, Moradi N, Golmohammadi T, Merat S. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep. 2018;8:11691.","journal-title":"Sci Rep"},{"key":"1974_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0021-9150(87)90091-8","volume":"68","author":"P Puchois","year":"1987","unstructured":"Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, Koren E, et al. Apolipoprotein A-1 containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35\u201340.","journal-title":"Atherosclerosis"},{"key":"1974_CR26","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.atherosclerosis.2010.01.001","volume":"210","author":"S Van Linthout","year":"2010","unstructured":"Van Linthout S, Foryst-Ludwig A, Spillmann F, Peng J, Feng Y, Meloni M, et al. Impact of HDL on adipose tissue metabolism and adiponectin expression. Atherosclerosis. 2010;210:438\u201344.","journal-title":"Atherosclerosis"},{"key":"1974_CR27","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1572-0241.2008.01888.x","volume":"103","author":"A Floreani","year":"2008","unstructured":"Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am J Gastroenterol. 2008;103:1959\u201365.","journal-title":"Am J Gastroenterol"},{"key":"1974_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0021-9150(97)06108-X","volume":"131","author":"MJ O'Kane","year":"1997","unstructured":"O\u2019Kane MJ, Lynch PL, Callender ME, Trimble ER. Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis. Atherosclerosis. 1997;131:203\u201310.","journal-title":"Atherosclerosis"},{"key":"1974_CR29","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/hep.28843","volume":"65","author":"S Petta","year":"2017","unstructured":"Petta S, Wong VW, Camm\u00e0 C, Hiriart JB, Wong GL, Marra F, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology. 2017;65:1145\u201355.","journal-title":"Hepatology"},{"key":"1974_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/liv.12282","volume":"34","author":"YE Chon","year":"2014","unstructured":"Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int. 2014;34:102\u20139.","journal-title":"Liver Int"},{"key":"1974_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/2053","volume":"4","author":"K Moriya","year":"1998","unstructured":"Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998;4:1065\u20137.","journal-title":"Nat Med"},{"key":"1974_CR32","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1111\/apt.14960","volume":"48","author":"YH Kuo","year":"2018","unstructured":"Kuo YH, Kee KM, Wang JH, Hsu NT, Hsiao CC, Chen Y, et al. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study. Aliment Pharmacol Ther. 2018;48:993\u20131002.","journal-title":"Aliment Pharmacol Ther"},{"key":"1974_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/apt.15575","volume":"51","author":"CC Wang","year":"2020","unstructured":"Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020;51:216\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"1974_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.arcmed.2006.09.001","volume":"38","author":"E Bj\u00f6rnsson","year":"2007","unstructured":"Bj\u00f6rnsson E, Angulo P. Hepatitis C and steatosis. Arch Med Res. 2007;38:621\u20137.","journal-title":"Arch Med Res"},{"key":"1974_CR35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1517\/14728222.2014.997711","volume":"19","author":"WY Liu","year":"2015","unstructured":"Liu WY, Xie DM, Zhu GQ, Huang GQ, Lin YQ, Wang LR, et al. Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target. Expert Opin Ther Targets. 2015;19:675\u201385.","journal-title":"Expert Opin Ther Targets"},{"key":"1974_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","volume":"69","author":"S Lemoinne","year":"2020","unstructured":"Lemoinne S, Kemgang A, Ben Belkacem K, Straube M, Jegou S, Corpechot C, et al. Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. Gut. 2020;69:92\u2013102.","journal-title":"Gut"},{"key":"1974_CR37","doi-asserted-by":"publisher","first-page":"7683","DOI":"10.3748\/wjg.v21.i25.7683","volume":"21","author":"VI Reshetnyak","year":"2015","unstructured":"Reshetnyak VI. Primary biliary cirrhosis: clinical and laboratory criteria for its diagnosis. World J Gastroenterol. 2015;21:7683\u2013708.","journal-title":"World J Gastroenterol"},{"key":"1974_CR38","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","volume":"116","author":"T Kadowaki","year":"2006","unstructured":"Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784\u201392.","journal-title":"J Clin Invest"},{"key":"1974_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1172\/JCI200317797","volume":"112","author":"A Xu","year":"2003","unstructured":"Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat- derived hormone adiponection alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91\u2013100.","journal-title":"J Clin Invest"},{"key":"1974_CR40","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/hep.1840150518","volume":"15","author":"JS Crippin","year":"1992","unstructured":"Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the Risk? Hepatology. 1992;15:858\u201362.","journal-title":"Hepatology"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01974-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01974-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T14:57:54Z","timestamp":1699714674000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01974-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1974"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01974-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"8 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this retrospective study, the requirement for informed consent was waived, and approval was granted by the ethical committee of the Beijing Youan Hospital, Capital Medical University. The study protocol confirmed to the ethical guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}